tbuckley/cabot-search huggingface dataset:
Oral Bisphosphonates and Improved Survival of Breast Cancer
Authors: Gad Rennert, Mila Pinchev, Naomi Gronich, Walid Saliba, Anath Flugelman, Idit Lavi, Hadassah Goldberg, Georgeta Fried, Mariana Steiner, Arie Bitterman, Keren Landsman, Hedy S. Rennert
Journal: Clinical Cancer Research (2016)

Purpose: Bisphosphonates are used for treatment or prevention of osteoporosis and of bone metastases. The use of oral bisphosphonates was suggested to be associated with reduced risk of developing breast cancer, and their positive influence on breast cancer survival was only demonstrated with third-generation bisphosphonates. We studied the association of use of oral bisphosphonates after breast cancer diagnosis on overall and breast cancer survival.Experimental Design: A nested case-control analysis was performed using data from the population-based Breast Cancer in Northern Israel Study (BCINIS). Participants were postmenopausal women with newly diagnosed breast cancer insured by Clalit. Use of second-generation bisphosphonates (alendronate and/or risedronate) was identified using computerized prescription records. The analysis was restricted to women who did not use bisphosphonates prior to diagnosis.Results: In a cohort of 3,731 postmenopausal women with breast cancer, followed up for an average of 70 months, there were 799 cases of death which were matched to 15,915 control periods of living breast cancer cases. Use of bisphosphonates after diagnosis for at least 18 months was significantly more common among survivors than among their matched controls who died, adjusted for tumor stage/grade (overall survival: OR = 0.63, 0.41-0.96, P = 0.03; breast cancer-specific survival: OR = 0.28, 0.09-0.91, P = 0.035). A similar advantageous effect, but statistically underpowered, was found in estrogen receptor (ER)-positive, ER-negative, and HER2neu-positive tumors.Conclusions: The use of oral bisphosphonates, by postmenopausal, probably osteoporotic, women initiated after diagnosis of breast cancer was associated with a significant improvement in overall and breast-specific odds of survival. Clin Cancer Res; 23(7); 1684-9. ©2016 AACR.
Toward Greater Implementation of the Exposome Research Paradigm within Environmental Epidemiology
Authors: Jeanette A. Stingone, Germaine M. Buck Louis, Shoji F. Nakayama, Roel C.H. Vermeulen, Richard K. Kwok, Yuxia Cui, David M. Balshaw, Susan L. Teitelbaum
Journal: Annual Review of Public Health (2017)

Investigating a single environmental exposure in isolation does not reflect the actual human exposure circumstance nor does it capture the multifactorial etiology of health and disease. The exposome, defined as the totality of environmental exposures from conception onward, may advance our understanding of environmental contributors to disease by more fully assessing the multitude of human exposures across the life course. Implementation into studies of human health has been limited, in part owing to theoretical and practical challenges including a lack of infrastructure to support comprehensive exposure assessment, difficulty in differentiating physiologic variation from environmentally induced changes, and the need for study designs and analytic methods that accommodate specific aspects of the exposome, such as high-dimensional exposure data and multiple windows of susceptibility. Recommendations for greater data sharing and coordination, methods development, and acknowledgment and minimization of multiple types of measurement error are offered to encourage researchers to embark on exposome research to promote the environmental health and well-being of all populations.
P0766 : Epidemiology of viral resistance in genotype 1 infected patients at approval of IFN-free DAA combination therapy of chronic hepatitis C in Germany
Authors: H. Farnik, J. Vermehren, S. Susser, J. Dietz, D. Perner, C. Berkowski, S. Zeuzem, C. Sarrazin
Journal: Journal of Hepatology (2015)
A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected non-small cell lung cancer (NSCLC).
Authors: M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades, M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. Monzo
Journal: Journal of Clinical Oncology (2011)

10587 Background: miRNAs play an important role in carcinogenesis through the regulation of different genes. miR-SNPs are a novel class of SNPs that can affect miRNA biogenesis and miRNA target sites and can alter miRNA expression and functions. We have evaluated 11 miR-SNPs in a series of 175 resected NSCLC p and correlated our findings with TTR. Methods: In 175 NSCLC p who underwent complete surgical resection between March 1996 and December 2009, we examined 11 miR-SNPs: 5 in miRNA genes (miR-194-2 rs11231898; miR-196a-2 rs11614913; miR-149 rs2292832; miR-423 rs6505162; miR-146a rs2910164); 3 in miRNA binding sites (KRT81 rs3660; FAM179B rs1053667; AFF1 rs17703261) and 3 in miRNA-processing machinery (XPO5 rs11077; RAN rs14035; TRBP rs784567). DNA was obtained from paraffin-embedded or fresh frozen tumor tissue and allelic discrimination assay with ABI Prism 7500 was performed. Results: p characteristics: mean age, 65 (35-85); 88% male; 149 (85.1%) PS 1; 98 (56%) stage I, 40 (22.9%) stage II, 37 (21.1%) stage III; 80 (45.7%) adenocarcinoma, 84 (48%) squamous cell carcinoma, 11 (6.3%) other histologies; 28 (16%) received adjuvant treatment, 9 (5.1%) received neoadjuvant treatment; mean follow-up 35 months (m); 75 (42.9%) p relapsed. Only stage (P=0.008) and KRT81 genotype were associated with TTR. Median TTR for 45 p (25.9%) with the CC genotype was 20.3 m vs 86.8 m for p with the CG or GG genotype (P=0.003). Among 98 p with stage I disease, median TTR was 23.9 m for 25 p (25.5%) with the CC genotype vs 100.2 m for p with the CG or GG genotype (P=0.002). In the multivariate analysis, KRT81 CC genotype (OR, 2.14; 95%CI, 1.29-3.55; P=0.003), stage I disease (OR, 0.36; 95%CI, 0.18-0.73; P=0.005) and male sex (OR, 5.25; 95%CI, 1.56-17.73; P=0.008) emerged as independent variables for TTR. Conclusions: KRT81 rs3660 SNP may be a novel marker for TTR in resected NSCLC, mainly in stage I, where it can help to detect high-risk patients who may be candidates for adjuvant treatment.
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer
Authors: A. M. Carella
Journal: Journal of Clinical Oncology (2008)

12002 The benefits of allografting noted in some malignant diseases might be safely extended to metastatic breast cancer by a combination of cytoreduction with high-dose chemotherapy (HDT) and autologous stem-cell transplant (ASCT) with graft-versus-tumour effect mediated by transplanted donor immune cells with nonmyeloablative allografting (reduced intensity conditioning transplantation, RICT). Twenty patients with heavily pretreated disease were given tandem transplants. Sixteen patients sustained donor engraftment. Four had partial remission after HDT and ASCT and complete remission after RICT; they achieved full chimerism and all developed graft-versus-host disease (GVHD) before regression of cancer. Another patient did not respond to HDT and ASCT but had partial remission after RICT, giving an overall response rate of 24%. Seven patients had grade II or higher acute GVHD and nine had extensive chronic GVHD. No non-relapse-related deaths occurred during the first 100 days. Four patients died of extensive cGVHD/infections. Six patients died early from disease progression (<4 months after RICT). At October 2007 six patients (31%) are alive at a median of 2035 days (range, 270–3,420): 3 patients achieved complete remission and are now alive CR at 270, 2,580 and 3,420 day; one patient in CR (2,330) developed colon cancer and 2 patients are in stable disease at 1,350 and 1,740 days. A.M. Carella et al. The Lancet 2005;366:318–320. A.M. Carella and M. Bregni. Ann Oncol 2007;18:1591–15933. A.M. Carella, et al. Ann Oncol 2007; 18:1751–1754 No significant financial relationships to disclose.
Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with First-Line BEV + CT (ML18147): Efficacy and Safety Analyses by Oxaliplatin vs Irinotecan-Based CT
Authors: P. Österlund, V. Alonso-Orduna, C. Schlichting, T. André, J. Sastre, R. Greil, S. Kubicka, I. Reyes-Rivera, B. McCall, E.J.D. Van Cutsem
Journal: Annals of Oncology (2012)
P1-161: Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer
Authors: Emilio Bria, Paolo Visca, Flavia Novelli, Barbara Antoniani, Raffaele Perrone-Donnorso, Isabella Sperduti, Francesco Facciolo, Michele Milella, Francesco Cognetti, Marcella Mottolese
Journal: Journal of Thoracic Oncology (2007)
Serial Changes in Cognitive Function Following Transcatheter Aortic Valve Replacement
Authors: Vincent Auffret, Francisco Campelo-Parada, Ander Regueiro, María Del Trigo, Olivier Chiche, Chekrallah Chamandi, Ricardo Allende, Juan G. Cordoba-Soriano, Jean-Michel Paradis, Robert De Larochellière, Daniel Doyle, Eric Dumont, Siamak Mohammadi, Mélanie Côté, Alier Marrero, Rishi Puri, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2016)
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803
Authors: N. A. Jackson, C. S. Fuchs, D. Niedzwiecki, D. R. Hollis, L. B. Saltz, R. J. Mayer, J. A. Meyerhardt
Journal: Journal of Clinical Oncology (2008)

4039 Background: Although tobacco use is linked to the development of colon cancer, little is known about its impact in colon cancer survivors. Methods: We prospectively collected data on prior and current cigarette smoking on 1,045 patients with stage III colon cancer enrolled in a phase III adjuvant chemotherapy trial (bolus 5-FU/leucovorin ± irinotecan). Patients (pts) reported tobacco use in self- report questionnaires during (Q1) & 6 months after completion of adjuvant therapy (Q2). Smoking status was defined as never, current, or past. Lifetime pack years (pyr) were defined as # of packs of cigarettes over pt’s lifetime. Since there was no difference in efficacy between the two treatments, data for all patients were combined. Cox proportional hazards were computed for disease-free survival (DFS, our primary endpoint) and overall survival (OS). DFS and OS were measured from completion of Q1 to event of interest, excluding events within the 1st 90 days to avoid biases of change in behavior due to impending event. Results: Data on smoking history were captured on 1,045 patients of 1,264 in the phase III trial (460 [44%] past smokers; 107 [10%] current smokers; 478 [46%] never smokers). In analyses adjusted for age, N and T stage, grade of differentiation, and presence of bowel obstruction at dx, past smokers had hazard ratio (HR) for DFS of 1.15 (95% CI, 0.92–1.43; p=0.2) and current smokers had HR for DFS of 1.20 (95% CI, 0.85–1.70; p=0.3), compared to never smokers. Consistent with prior analyses, we defined pyr categories as 0, 0–10, 10–20, 20 or more. In unadjusted analyses, HR for DFS were 1.16 (95% CI, 0.89–1.52), 1.24 (95% CI, 0.85–1.83) and 1.33 (95% CI, 1.03–1.73) for lifetime pyr 0–10, 10–20 and 20+, respectively, compared to never smoking (p trend 0.04). In adjusted analyses, HR for 20+ pyr was 1.25 (95% CI, 0.96–1.63) compared to never smoking (p trend 0.15). HRs for OS were similar as DFS for smoking status and lifetime pyr. Conclusions: Lifetime total of tobacco usage may influence outcomes in patients with stage III colon cancer. Further research with larger datasets is warranted. No significant financial relationships to disclose.
Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation
Authors: I. Tinhofer, A. Stenzinger, T. Eder, R. Konschak, F. Niehr, V. Endris, L. Distel, M.G. Hautmann, R. Mandic, C. Stromberger, W. Weichert, V. Budach
Journal: Annals of Oncology (2016)
Primary Outcomes of the EVOLVE II Trial: A Prospective Randomized Investigation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent
Authors: Dean J Kereiakes, Ian T Meredith, Stephan Windecker, R. Lee Jobe, Shamir R Mehta, Ian J Sarembock, Robert L Feldman, Christophe Dubois, Timothy Grady, Shigeru Saito, Takeshi Kimura, Thomas Christen, Dominic J Allocco, Keith D Dawkins
Journal: Circulation (2014)
Characterization of Molecular Abnormalities in Human Fibroblastic Neoplasms
Authors: Axel Hoos, Jonathan J. Lewis, Cristina R. Antonescu, Maria E. Dudas, Larry Leon, James M. Woodruff, Murray F. Brennan, Carlos Cordon-Cardo
Journal: Cancer Research (2001)

Desmoid tumors and fibrosarcomas (FS) are part of a wide spectrum of disordered fibroblastic growth that display striking clinical and phenotypic differences. This study was designed to characterize molecular abnormalities that are associated with these differences and to determine their clinical relevance. A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (HG) FS that were clinically and pathologically well characterized was analyzed for alterations in expression of Ki-67, Bcl-2, retinoblastoma gene product (pRB), and p53 by immunohistochemistry. LG-FS and HG-FS showed abnormal expression of Ki-67 (32 versus 86%), Bcl-2 (48 versus 57%), and pRB (56 versus 93%). In contrast, desmoid tumors showed a normal phenotype with these markers. p53 overexpression was identified in 20% of LG-FS and in 29% of HG-FS cases but only in 4% of desmoid tumors. There was an increasing trend in the proportion of abnormal expression of Ki-67, Bcl-2, pRB, and p53 with the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS. The molecular differences between tumor entities were highly statistically significant ( P  5 cm were observed ( P = 0.02). The demonstrated differences of molecular alterations in HG-FS, LG-FS, and desmoids appear to be related to biological aggressiveness of such tumors, and they might be useful to differentiate between histologically similar cases of desmoid tumors and LG-FS. pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients.
Validation of the "surprise question" in gynecologic oncology: Comparing physicians, advanced practice providers and nurses.
Authors: Carolyn Lefkowits, Chelsea Chandler, Paniti Sukumvanich, Madeleine Courtney-Brooks, Linda R. Duska, Andrew Althouse, Joseph L Kelley
Journal: Journal of Clinical Oncology (2015)

151 Background: The “surprise question” – “Would you be surprised if this patient died in the next year?” has been validated in non-gynecologic cancer as highly predictive of 12-month mortality. It has been used as a major inclusion criterion in studies showing benefit to specialized palliative care. It has not been studied in the gynecologic oncology (GO) population or with non-physician providers. Our objectives were to (1) evaluate the prognostic significance of the surprise question in GO patients and (2) compare the performance of the surprise question among different provider groups. Methods: The surprise question was asked of a group of 18 GO providers from a single academic institution (7 physicians, 7 advanced practice providers (APP) and 4 chemotherapy nurses (RN)) regarding their patients currently receiving radiation or chemotherapy. Demographic and clinical data were abstracted from chart review and mortality data was collected 12 months later. Results: The 263 patients included had a median age of 64 and the majority were white (94%). The most common cancer was ovary (50%), 58% had stage III/IV disease and 46% had recurrent disease. There were 54 deaths (20.5% one-year mortality). Risk of mortality was significantly higher for patients with a response of “No” to the surprise question from the MD (40% vs 10.6%, p &lt; 0.01), APP (43.2% vs 7.6%, p &lt; 0.01) and RN (50.8% vs 13.1%, p &lt; 0.01). The unadjusted odds ratio for death within a year associated with a “No” answer to the surprise question by provider were as follows: MD OR 5.6 (p &lt; 0.001), APP 9.21 (p &lt; 0.001), RN 6.86 (p &lt; 0.001). The APP group had the highest sensitivity (79.5%), while the RN group had the best specificity (75.6%). Conclusions: The surprise question is a simple, feasible and effective tool to identify patients with gynecologic cancer who have a greatly increased risk of 12-month morality when administered by physicians, advanced practice providers or chemotherapy nurses. This one question screen could be used to identify patients appropriate for early referral to specialized palliative care or patients in whom to consider initiating conversations about goals of care and advanced care planning.
Aspirin and Acute Respiratory Distress Syndrome
Authors: Robert A. Kuschner
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postoperation chemotherapy with S1 and docetaxel in curatively resected gastric cancer of stage III (POST trial).
Authors: Minkyu Jung, Seok Yun Kang, Bong-Seog Kim, Ki Hyang Kim, Kyung Hee Lee, Moon Hee Lee, Dong Bok Shin, Dae Young Zang, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Journal: Journal of Clinical Oncology (2012)

TPS4142 Background: Complete surgical resections remains the only chance for cure in patients with gastric cancer, but approximately from 40% to 80% of patients still have recurrences and most patients ultimately die from their disease. The recent adjuvant trials in gastric cancer showed significantly improved survival in patients with adjuvant chemotherapy than those with surgery alone. However, further studies need for the effect of adjuvant chemotherapy following D2 dissected gastric cancer patients, especially in advanced gastric cancer. S-1 is an oral anticancer drug, a prodrug of fluorouracil, very effective in gastric cancer. Docetaxel is the first drug that showed survival benefits when added to the two drugs in advanced gastric cancer patients. And docetaxel is also synergistic anti-cancer effect with S-1 in advanced gastric cancer. Base on this background, the aim of this study is to detect a significant increase in 3 –year disease free survival (DFS) of adjuvant chemotherapy with docetaxel and S-1(DS) relative to those with S-1 and cisplatin (SP) in patients with stage III gastric cancer Methods: This study is an open-label, phase 3, randomized controlled trial, multicenter in South Korea. Patients with stage III (AJCC 7 th edition) gastric cancer who had had curative D2 gastrectomy is randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of intravenous docetaxel (35 mg/m 2 on day 1 and 8 of each cycle) plus oral S-1 (35 mg/m 2 twice daily on days 1 to 14 of each cycle) for 6 months (DS) or chemotherapy of eight 3-week cycles of oral S1 plus intravenous cisplatin (60 mg/m 2 ). After satisfying the screening criteria, patients have been randomized to the SD or SP arm in a 1:1 ratio. The randomization is stratified by institution and stage of disease (IIIA vs. IIIB vs. IIIC). The each stratum has been randomized by using the method of randomly permuted block. The primary endpoint is 3 year DFS, will analyze by intention to treat. A total of 290 patients will be enrolled, 67 patients have been treated to day, with continuing accrual. The trial is registered at ClinicalTrials.gov (NCT01283217).
Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma
Authors: R. Kitagawa, N. Katsumata, Y. Yamanaka, M. Ando, Y. Fujiwara, T. Kasamatsu, T. Onda, T. Yamada, R. Tsunematsu, T. Watanabe
Journal: Journal of Clinical Oncology (2004)

5048 Background: For patients (pts) with recurrent or metastatic cervical carcinoma, T plus cisplatin (P) were reported to improve the response rate (RR) and progression-free interval compared to P alone (Moore et al; Proc ASCO 2001) and has been shown as a new appropriate regimen. However, more effective and/or less toxic combinations are needed. C as a single agent has less RR but less overall toxicity than P. In order to evaluate the efficacy and safety of T plus C, we conducted the following phase II trial. Methods: Pts with recurrent or metastatic cervical carcinoma no longer amenable to curable surgery or radiatiotherapy (RTx), with measurable lesions, performance status (PS) 0–2, and adequate organ functions, received TC (paclitaxel 175mg/m2 3-hour i.v., carboplatin AUC 5 1-hour i.v.) every 3 weeks. Treatment was continued until progression or completion of 6 courses administration. Tumor response was evaluated every 2 cycles, and toxicities every cycle. Results: 28 pts (median age 49; range 29–67) were enrolled and 23 pts were assessable for response and toxicities. 21 pts (91%) had received RTx. The overall RR was 61% (95% CI, 41–78%), especially CR showed in 2 pts (9%). The median progression-free survival was 5.9 months (range 1.0–14.1). RRs according to PS, histological type (Hx), prior RTx for target lesions, and prior chemotherapy (CTx) are given in the table below. As day 1 hematological toxicities, Grade 4 was observed only in Anemia (4 pts; 17%). Non-hematological toxicity included grade 3 neuropathy in 2 pts (8%). Grade 3 febrile neutropenia was observed in 3 pts (13%), but they were managed without hospitalization or G-CSF administration. Conclusions: TC is promising and feasible combination in pts with recurrent or metastatic cervical carcinoma and can be safely administered in outpatient clinic. On this basis, phase III study is planed to compare TC with T plus P. No significant financial relationships to disclose.
P1.08: Updated Analysis of Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
Authors: Gustavo Werutsky, Marcio Debiasi, Fernanda H. Sampaio, Paulo R. Nunes Filho, Clarissa Mathias, Mauro Zukin, Facundo Zaffaroni, Gilberto Lopes
Journal: Journal of Thoracic Oncology (2016)